论文部分内容阅读
目的:观察分析尿激酶溶栓治疗急性心肌梗死的临床疗效,总结其临床应用价值。方法:选取我院2009年4月至2011年4月34例急性心肌梗死患者,随机分为观察组和对照组各17例。对照组采用基础性治疗,观察组在对照组治疗的基础上加用尿激酶溶栓治疗,观察比较两组疗效。结果:观察组血管再通率明显高于对照组,严重心律失常发生率低于对照组,无心力衰竭、休克及死亡案例发生。结论:尿激酶溶栓治疗急性心肌梗死的临床疗效显著,明显优于基础性治疗的效果,能显著提高血管再通率,降低心血管事件的发生率,降低病死率,不良反应小,安全可靠,值得在临床上合理推广。
Objective: To observe the clinical efficacy of urokinase thrombolysis in the treatment of acute myocardial infarction and to summarize its clinical value. Methods: A total of 34 patients with acute myocardial infarction from April 2009 to April 2011 in our hospital were randomly divided into observation group (17 cases) and control group (17 cases). The control group with the basic treatment, the observation group in the control group based on the addition of urokinase thrombolysis, observed and compared the efficacy of the two groups. Results: The recanalization rate of the observation group was significantly higher than that of the control group. The incidence of severe arrhythmia was lower than that of the control group. No heart failure, shock and death occurred. Conclusion: The clinical efficacy of urokinase thrombolytic therapy for acute myocardial infarction was significantly better than that of basic treatment, which can significantly improve the rate of recanalization, reduce the incidence of cardiovascular events, reduce the mortality, adverse reactions, safe and reliable , It is worth in the clinical reasonable promotion.